Onconova Therapeutics, Inc. Warrants
ONTXW
ONTXW was delisted on the 23rd of July, 2021.
2 hedge funds and large institutions have $7K invested in Onconova Therapeutics, Inc. Warrants in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
53% less capital invested
Capital invested by funds: $15K → $7K (-$8K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$5.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.77K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$4K |
ONTXW Hedge Fund Activity: Q2 2021 in Review
2 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Onconova Therapeutics, Inc. Warrants (ONTXW) for Q2 2021, worth a combined $7K — down 53% from $15K a quarter earlier.
Fund positioning in ONTXW was balanced in Q2 2021: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $5.72K. The largest seller was UBS Group, cutting an estimated $4.77K.
- 2 institutional investors held Onconova Therapeutics, Inc. Warrants (ONTXW) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $7K of Onconova Therapeutics, Inc. Warrants stock for Q2 2021, down 53% quarter-over-quarter.
- 1 fund opened new Onconova Therapeutics, Inc. Warrants positions in Q2 2021 and 1 closed out, a net change of 0 holders.
- The largest Onconova Therapeutics, Inc. Warrants buyer in Q2 2021 was Virtu Financial, an estimated $5.72K added.
- The largest Onconova Therapeutics, Inc. Warrants seller in Q2 2021 was UBS Group, an estimated $4.77K sold.
Based on aggregated 13F filings for Q2 2021.